Suggested Remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating Waldenström’s macroglobulinaemia.
 
Status In progress
Decision Selected
Process STA 2018
ID number 1427

Provisional Schedule

Expected publication 19 October 2022

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors BeiGene
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Lymphoma Action
  WMUK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Janssen-Cilag
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
09 August 2022 Committee meeting: 2
29 June 2022 - 20 July 2022 Draft guidance: 2
07 June 2022 Committee meeting: 2
06 May 2022 - 26 May 2022 Draft guidance
12 April 2022 Committee meeting: 1
09 December 2021 The appraisal timelines have now been updated and the first appraisal committee meeting is now scheduled to take place on 12 April 2022.
24 June 2021 NICE have taken the decision to pause this appraisal due to operational reasons, timelines are currently to be confirmed.
15 February 2021 The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission.
27 October 2020 Invitation to participate
23 July 2020 - 20 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 July 2017 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual